News
-
Inhaled insulin developer Dance Biopharm has announced the appointment of former Excelsior Medical President and CEO Steve Thornton to its board of directors. Thornton was also previously President and CEO of Bioniche Pharma and President… Read more . . .
-
DPI device developer Iconovo AB announced that it has raised €.2.3 million in an oversubscribed share issue, which the company will use to fund expansion of its services to include drug formulation development. As part… Read more . . .
-
According to Spyryx Biosciences, Cystic Fibrosis Foundation Therapeutics (CFFT) will increase a development award to Spyryx to provide a total of up to $5 million. The company said that it plans to use the funds… Read more . . .
-
Boehringer Ingelheim has filed a citizen petition with the FDA asking the agency to “request the Commissioner of Food and Drugs to ensure that any New Drug Application (“NDA”) for a fixed-dose, triple-combination, inhaled drug… Read more . . .
-
Consort Medical, parent company of device manufacturer Bespak and CDMO Aesica, has announced that its pre-tax profits for fiscal year 2017 almost doubled from FY 2016, rising from £11.3 million to £21.9 million. Bespak earnings… Read more . . .
-
Medical Developments International (MVP) has announced that Health Canada has accepted its submission for the Penthrox methoxyflurane inhaler, triggering a $250,000 Canadian milestone payment to MVP from Purdue Pharma Canada. In September 2016, MVP announced… Read more . . .
-
According to Novartis, the FDA has accepted Sandoz’s abbreviated new drug application for its generic version of the Advair Discus (Seretide Accuhaler) fluticasone propionate/salmeterol DPI for the treatment of asthma and COPD. The company acquired… Read more . . .
-
The 21st Congress of the International Society for Aerosols in Medicine (ISAM), held in Santa Fe, New Mexico June 3-7, 2017 featured presentations and posters covering recent advances in a wide range of topics related… Read more . . .
-
Sun Pharma Advanced Research Company Ltd. (SPARC) has announced that its SPARC DPI salmeterol 25 µg/fluticasone propionate 50 µg dry powder inhaler failed to show bioequivalence to Seretide Accuhaler (Advair Diskus) salmeterol 50 µg/fluticasone propionate… Read more . . .
-
Inhaled drug developer Pulmatrix announced that it has licensed a portfolio of kinase inhibitors from Janssen Biotech subsidiary RespiVert that it plans to develop as inhaled therapies for respiratory diseases. According to a form filed… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
No events are found.